Literature DB >> 22679564

Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

Oluwole Fadare, Wenxin Zheng.   

Abstract

Entities:  

Year:  2012        PMID： 22679564      PMCID： PMC3365804     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


× No keyword cloud information.
  50 in total

1.  Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.

Authors:  J Bourhis; R Lubin; B Roche; S Koscielny; J Bosq; I Dubois; M Talbot; P Marandas; G Schwaab; P Wibault; B Luboinski; F Eschwege; T Soussi
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

Review 2.  A proposed model for endometrial serous carcinogenesis.

Authors:  Wenxin Zheng; Li Xiang; Oluwole Fadare; Beihua Kong
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

3.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.

Authors:  D T Wheeler; K A Bell; R J Kurman; M E Sherman
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

4.  Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.

Authors:  J Laudanski; T Burzykowski; W Niklinska; K Chyczewski; M Furman; J Niklinski
Journal:  Lung Cancer       Date:  1998-12       Impact factor: 5.705

5.  HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.

Authors:  W Glenn McCluggage; Lynette E Connolly; Hilary A McBride; Steve Kalloger; C Blake Gilks
Journal:  Histopathology       Date:  2012-01-17       Impact factor: 5.087

6.  Stage I serous papillary carcinoma of the endometrium.

Authors:  H H Gallion; J R van Nagell; D F Powell; E S Donaldson; R V Higgins; R J Kryscio; E J Pavlik; K Nelson
Journal:  Cancer       Date:  1989-06-01       Impact factor: 6.860

7.  p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma.

Authors:  W Zheng; R Khurana; S Farahmand; Y Wang; Z F Zhang; J C Felix
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

8.  Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.

Authors:  Lin Jia; Yongjuan Liu; Xiaofang Yi; Alexander Miron; Christopher P Crum; Beihua Kong; Wenxin Zheng
Journal:  Clin Cancer Res       Date:  2008-03-27       Impact factor: 12.531

9.  The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Authors:  Wenxin Zheng; Xiaofang Yi; Oluwole Fadare; Sharon X Liang; Maritza Martel; Peter E Schwartz; Zhong Jiang
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

10.  Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma.

Authors:  Elke A Jarboe; Ellen S Pizer; Alexander Miron; Nick Monte; George L Mutter; Christopher P Crum
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842
View more
  4 in total

Review 1.  The emerging genomic landscape of endometrial cancer.

Authors:  Matthieu Le Gallo; Daphne W Bell
Journal:  Clin Chem       Date:  2013-10-29       Impact factor: 8.327

2.  Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma.

Authors:  Lin Jia; Zeng Yuan; Yiying Wang; Janiel M Cragun; Beihua Kong; Wenxin Zheng
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

Review 3.  Histopathologic diagnosis of endometrial precancers: Updates and future directions.

Authors:  Hao Chen; Amanda L Strickland; Diego H Castrillon
Journal:  Semin Diagn Pathol       Date:  2021-12-10       Impact factor: 3.893

4.  Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression.

Authors:  Suet-Ying Kwan; Chi-Lam Au-Yeung; Tsz-Lun Yeung; Angela Rynne-Vidal; Kwong-Kwok Wong; John I Risinger; Hui-Kuan Lin; Rosemarie E Schmandt; Melinda S Yates; Samuel C Mok; Karen H Lu
Journal:  Cancers (Basel)       Date:  2020-01-02       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.